

CURRICULUM VITAE

Name and Surname: HACER DEMİR

Academic Title: Associate Professor

Work Address:

Email: haker.demir@afsu.edu.tr

Area of Expertise: Health Sciences

PUBLICATIONS**A. Articles published in international peer-reviewed journals:**

- A1.** Culha Y., Ünlü B., Davarcı S. E., Güzel H. G., Demir H., Öztürk B., Baykara M., "Is the risk of brain metastasis and prognosis different in HER2-low breast cancer?", *Clinical and Translational Oncology*, vol. 28, no. 5, pp. 1624-1636, 2026.
- A2.** Ünlü B., Demir H., Davarcı S. E., Culha Y., Baykara M., "Prognostic Value of the Lung Immune Prognostic Index (LIPI) in Patients with Renal Cell Carcinoma: A Retrospective Cohort Study", *Journal of Clinical Medicine*, vol. 15, no. 3, pp. 1188, 2026.
- A3.** Kahraman S., Erul E., Gumusay O., Guven D. C., Aksoy S., Basaran G., Seyyar M., Sahin E., Cabuk D., Bayram E. vd., "Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study", *Clinical Breast Cancer*, vol. 25, no. 5, 2025.
- A4.** Culha Y., Davarcı S. E., Ünlü B., Özaşkın D., Demir H., Baykara M., "Comparison of clinicopathological and prognostic features of breast cancer patients younger than 40 years and older than 65 years", *Discover Oncology*, vol. 15, no. 1, 2024.
- A5.** Ozdemir C. Y., Arioz D. T., Cicekli N., Chkhikvadze M., Bilir F., Özdemir Ç., Demir H., Arıkan Söylemez E. S., "Retrospective Analysis of Molecular Markers in Endometrial Cancer: Single Center Experience", *Clinical and Experimental Obstetrics and Gynecology*, vol. 51, no. 2, 2024.
- A6.** Karaçin C., Öksüzöğlu B., Demirci A., Keskinçilic M., Baytemür N. K., Yılmaz F., Selvi O., Erdem D., Avcı E., Paksoy N. vd., "Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (BMC Cancer, (2023), 23, 1, (136), 10.1186/s12885-023-10609-8)", *BMC Cancer*, vol. 23, no. 1, pp. 12885-13023, 2023.
- A7.** Avcı O., İriağaç Y., Çavdar E., Karaboyun K., Araz M., Şakalar T., Değerli E., Özdemir Ö., İnal A., Ocak B. vd., "PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study", *Journal of Geriatric Oncology*, vol. 14, no. 8, pp. 1-7, 2023.
- A8.** Bilir F., Arıoz D. T., Arıkan Söylemez E. S., Yalçın G. Ş., Özdemir Ç., Demir H., Chkhikvadze M., Ozdemir C. Y., Çiçekli N., Vatansever N. vd., "Relationship between molecular markers and lymphadenectomy and lymphovascular space invasion in endometrial cancer", *Archives of Gynecology and Obstetrics*, vol. 308, no. 3, pp. 941-946, 2023.
- A9.** Aydın S., Balci A., Dumanlı A., Acar L. N., Aysin M., Gencer A., Öz G., Demir H., Davarcı S. E., "The effect of high standard uptake value in lung cancer metastatic lesions on survival", *Croatian Medical Journal*, vol. 64, no. 3, pp. 179-185, 2023.
- A10.** Bilici A., Koca S., Karaağaç M., Göktas Aydın S., Eraslan E., Kaplan M. A., Ocak B., Sezgin Göksu S., Paydaş S., Akgül F. vd., "Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study", *Journal of Cancer Research and Clinical Oncology*, vol. 149, pp. 8243-8253, 2023.
- A11.** Kahraman S., Erul E., Seyyar M., Gumusay O., Bayram E., Demirel B. C., Acar O., Aksoy S., Baytemur N. K., Sahin E. vd., "Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer", *Future Oncology*, 2023.
- A12.** Davarcı S. E., Demir H., Demirbaş A., Yalçın G. Ş., Özdemir Ç., Özgül E., Baykara M., "Sarcomatoid urothelial carcinoma accompanied by elevated serum β -HCG: Two case reports Sarcomatoid urothelial carcinoma with elevated serum β -HCG", *ANNALS OF CLINICAL AND ANALYTICAL MEDICINE*, vol. 14, no. 1, pp. 112-115, 2023.
- A13.** Özdemir Ö., Zengel B., Yıldız Y., Oyan Uluç B., Çabuk D., Özden E., Kıvrak Salim D., Paydaş S., Demir A., Diker Ö. vd., "The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study", *Anti-Cancer Drugs*, vol. 33, no. 7, pp. 663-670, 2022.

- A14.** Beypınar I., Demir H., Araz M., Baykara M., Aykan N. F., "The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer", *Journal of Gastrointestinal Cancer*, vol. 53, no. 1, pp. 57-63, 2022.
- A15.** Küçük A., Demir H., Özdemir Ç., Beypınar İ., Baykara M., Arıöz D. T., "Microsatellite instability (MSI) in endometrial cancer; frequency and prognostic significance Microsatellite instability (msi) by immunohistochemistry in endometrial cancer", *ANNALS OF CLINICAL AND ANALYTICAL MEDICINE*, vol. 13, no. 2, pp. 230-235, 2022.
- A16.** Demir H., Demirci A., Eren S. K., Beypınar I., Davarcı S. E., Baykara M., "A New Prognostic Index in Young Breast Cancer Patients", *Journal of the College of Physicians and Surgeons Pakistan*, vol. 32, no. 1, pp. 86-91, 2022.
- A17.** Beypınar İ., Demir H., Sakin A., Yapar Taşköylü B., Şakalar T., Ergün Y., Korkmaz M., Ateş Ö., Eren T., Turhal S. vd., "The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study", *Journal of Gastrointestinal Cancer*, vol. 52, no. 3, pp. 932-939, 2021.
- A18.** Hafizoğlu M., Köroğlu R., Demir H., Bozkurt E., Hafizoğlu E., "The correlation of tumor markers, neutrophil/lymphocyte ratio and FDG PET/CT measures in pancreatic cancer", *TURKISH JOURNAL OF INTERNAL MEDICINE*, vol. 3, no. 3, pp. 95-101, 2021.
- A19.** Demir H., Törüner F., Bukan N., "The Effect of Serum Adiponectin and Cortisol Levels on Prognosis in the Patients with Sepsis and Septic Shock", *Eurasian Journal of Medical Investigation*, vol. 5, no. 1, pp. 153-158, 2021.
- A20.** Urvey S., Demir H., Gökyer A., Hacıbekiroğlu İ., Küçükarda A., Çakır E., Beypınar İ., Demir N., Civelek B., Özaslan E., "Investigation of the effect of tumor location in patients with stage iii colon cancer receiving adjuvant oxaliplatin-based adjuvant chemotherapy", *UHOD - Uluslararası Hematoloji-Onkoloji Dergisi*, vol. 31, no. 1, pp. 50-58, 2021.
- A21.** Alkan A., Güç Z. G., Gürbüz M., Özgün G., Değirmencioglu S., Doğan M., Akın Telli T., Keskin Ö., Arslan Ç., Bilgin B. vd., "Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥ 75) patients", *Journal of Men's Health*, vol. 17, no. 4, pp. 128-134, 2021.
- A22.** Bahçeci A., Paydaş S., Ak N., Ferhatoglu F., Saip P. M., Seydaoğlu G., Bilici M., Şimşek M., Tekin S. B., Çalıkuşu Z. vd., "Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience", *Cancer Investigation*, vol. 39, pp. 473-481, 2021.
- A23.** Demir H., Beypınar I., Urvey S., Davarcı S. E., Baykara M., "Prognostic role of pre-operative serum ferritin level in stage 2 colon cancer", *European Review for Medical and Pharmacological Sciences*, 2021.
- A24.** Yıldız B., Küçükarda A., Gökyer A., Demiray A. G., Paydaş S., Aral İ. P., Gümüşay Ö., Bilici A., Akdeniz N., Bahçeci A. vd., "Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study", *Journal of BUON*, vol. 25, no. 2, pp. 1130-1135, 2020.
- A25.** Demir A., Mandel N. M., Paydaş S., Demir G., Er Ö., Turhal N. S., Bavbek S., Eralp Y., Saip P. M., Güler E. N. vd., "Efficacy of palbociclib and endocrine treatment in heavily pretreated hormone receptor-positive/HER2-negative advanced breast cancer: Retrospective multicenter trial", *Balkan Medical Journal*, vol. 37, no. 2, pp. 104-107, 2020.
- A26.** Yıldız F., Eraslan E., İlhan A., Demir H., Demir N., Erdur E., Yildirim O. A., Kanmaz H., Aslan F., Tufan G. vd., "Perioperative docetaxel, oxaliplatin, fluorouracil, and leucovorin (Flot) in patients with gastric or esophagogastric junction adenocarcinoma; real-life experience", *UHOD - Uluslararası Hematoloji-Onkoloji Dergisi*, vol. 30, no. 3, pp. 155-161, 2020.
- A27.** Araz M., Beypınar İ., Beypınar D., Demir H., Uysal M., "Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer", *Eurasian Journal of Medicine and Oncology*, vol. 3, no. 2, pp. 112-115, 2019.
- A28.** Bilgetekin İ., Karaca M., Gönül I., Üner A., Şahinli H., Demir H., Aytekin A., Çiltaü A., Benekli M., "Ewing's sarcoma of kidney in a 60-year-old patient with local recurrence: A rare occurrence", *Journal of Cancer Research and Therapeutics*, vol. 14, no. 6, pp. 1422-1424, 2018.
- A29.** Karaca M., Koçoğlu H., Bilgetekin I., Ozet A., Şahinli H., Demir H., Kankoc A., Tural D., Yucel O., "Ventricular bigeminal rhythm associated with trastuzumab: A potential cardiac side effect", *Journal of Cancer Research and Therapeutics*, vol. 14, no. 9, pp. 536-537, 2018.
- A30.** Şenel F., Karaman H., Demir H., "Neuroendocrine tumors detected in appendectomy specimens: Ten-year single-center experience", *Turkish Journal of Medical Sciences*, vol. 48, no. 1, pp. 68-73, 2018.
- A31.** Özaslan E., Topaloğlu U. S., İnanç M., Erdem G. U., Demir H., Arpacı E., Şeker M. M., Karaağaç M., Kızıltepe M., Eker B. vd., "Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer", *Journal of BUON*, vol. 22, no. 4, pp. 863-868, 2017.
- A32.** Özaslan E., Karaca H., Koca S., Sevinç A., Hacıoglu B., Özkan M., Özçelik M., Duran A. O., Hacıbekiroğlu İ., Yıldız Y. vd., "Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less", *Anti-Cancer Drugs*, vol. 28, no. 2, pp. 222-229, 2016.

D. Articles published in national peer-reviewed journals:

- D1.** Demir H., Özdemir Ç., Baykara M., Demirci A., Beypınar İ., Davarcı S. E., Özdemir C. Y., Culha Y., Arıöz D. T., "THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA", *Kocatepe Tıp Dergisi*, vol. 27, pp. 1-9, 2026.
- D2.** Demir H., Beypınar İ., Öztürk D., Davarcı S. E., Baykara M., "LOCALIZE SCROTAL KAPOSI SARCOMA IN A HIV-NEGATIVE PATIENT", *Kocatepe Tıp Dergisi*, 2025.
- D3.** Culha Y., Baykara M., Davarcı S. E., Ünlü B., Özaşkın D., Demir H., "Metastatik Meme Kanseriinde Birinci Basamak Tedavi Sonuçlarının Değerlendirilmesi", *Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi*, vol. 20, 2025.

- D4.** Culha Y., Özdemir Ç., Davarcı S. E., Ünlü B., Olgun A. K. M., Demir H., Baykara M., "Clinical and prognostic effects of microvascular density and FOXP3 positive T cells in breast cancer", *Scientific Reports*, vol. 14, no. 1, 2024.
- D5.** Öztürk D., Özdemir C. Y., Çiçekli N., Özdemir Ç., Ünlü B., Demir H., Arıöz D. T., "Relationship Between p53 and Recurrence in Endometrial Cancer", *SDÜ Tıp Fakültesi Dergisi*, 2024.
- D6.** Demir H., Özgül E., Davarcı S. E., Baykara M., "Rare metastasis in a patient with BRAF-mutated rectal cancer: choroidal metastasis – case report and literature review", *GMS Ophthalmology Cases*, vol. 14, pp. 1-7, 2024.
- D7.** Özkul Ö., Şahin E., Çabuk D., Sever N., Majidova N., Bayoğlu İ. V., Culha Y., Demir H., Baykara M., Bilir C. vd., "The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer", *EURASIAN JOURNAL OF MEDICAL INVESTIGATION*, vol. 8, no. 1, pp. 58-66, 2024.
- D8.** Culha Y., Baykara M., Demir H., Davarcı S. E., Ünlü B., "Single Center Experience: Testicular Cancer Case Series", *Eurasian Journal of Medical Investigation*, vol. 7, no. 3, pp. 315-320, 2023.
- D9.** Yavaşoğlu F., Özdemir Ç., Şenol Y., Demir H., Baykara M., "A Single-center Experience of Synchronous and Metachronous Hematologic and Oncologic Tumors", *Osmangazi Journal of Medicine*, vol. 45, no. 6, pp. 853-861, 2023.
- D10.** Beypınar İ., Çoker B., Demir H., Uysal M., "The Comparison of Pre-diagnostic and Diagnostic Thrombocyte Levels in Pancreatic and Biliary Tract Cancers", *Journal of Anatolian Medical Research*, vol. 8, no. 8, pp. 22-25, 2023.
- D11.** Özdemir Ç., Şenol Y., Baykara M., Ak M. O., Demir H., Sarıkaya Y., "Here is the metastasis - find the primary carcinoma for it: a large biopsy study", *The European Research Journal*, vol. 9, 2023.
- D12.** Almuradova E., Yalçın Ş., Arıkan R., Ayhan M., Demir H., Çevik G. T., Karaca M., Petekkaya H. İ., Karabulut B., "Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study", *cureus*, vol. 15, no. 5, pp. 1-9, 2023.
- D13.** Ürün M., Beypınar İ., Davarcı S. E., Demir H., Baykara M., "The evaluation of vaccination status and the factors affecting vaccination in cancer patients", *Acta Medica Alanya*, 2022.
- D14.** Beypınar İ., Kaya F., Demir H., "The Effect of The Body Composition to Prognosis in Young Breast Cancer Patients", *Akdeniz Medical Journal*, vol. 7, no. 3, pp. 385-391, 2021.
- D15.** Demir H., Baykara M., Davarcı S. E., Arıöz D. T., Özdemir C. Y., Beypınar İ., "Uterin Karsinosarkomlar: Tek Merkez Deneyimi Uterine Carcinosarcomas: A Single Center Experience", *Eskisehir Med J.*, vol. 2, no. 2, pp. 82-88, 2021.
- D16.** Demir H., Beypınar İ., "Effect of systemic immune-inflammation index on prognostic parameters and survival in patients with breast cancer under the age of 40 years", *Medical Science and Discovery*, vol. 8, no. 1, pp. 39-44, 2021.
- D17.** Yıldız F., Ayhan M., Demir H., Yeşil Çinkır H., Aslan F., Tufan G., Öksüzöğlu Ö. B., "Comparing the efficacy of cabazitaxel in second-line and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey", *International Journal of Contemporary Medical Research*, vol. 7, no. 9, pp. 112-116, 2020.
- D18.** Demir H., Beypınar İ., Baykara M., "The Effect of the Prognostic Nutritional Index on Chemoradiotherapy Response in Lung Cancer", *Journal of Oncological Sciences*, vol. 6, no. 2, pp. 96-102, 2020.
- D19.** Beypınar İ., Demir H., Araz M., Beypınar D., Uysal M., "The Comparison of Central Venous Port Catheters in Gastrointestinal Cancer Treatment", *Journal of Oncological Sciences*, vol. 6, no. 1, pp. 10-14, 2020.
- D20.** Beypınar İ., Demir H., Araz M., Uysal M., "The relationship between EGFR mutation and metastasis pattern in lung adenocarcinoma", *Journal of Oncological Sciences*, vol. 5, pp. 65-69, 2019.
- D21.** Araz M., Demir H., Beypınar İ., "Is TTF-1 a Prognostic Marker in Non-Small Cell Lung Adenokarsinoma?", *Medicine Science*, vol. 8, no. 3, pp. 601-605, 2019.
- D22.** Araz M., Beypınar İ., Demir T., Demir H., Uysal M., "Reactivation risk of Hepatitis B Virus in both HBsAg negative and HBcIgG positive patients with solid malignancy. Is antiviral prophylaxis really necessary?", *Medicine Science*, vol. 8, no. 2, pp. 418-421, 2019.
- D23.** Demirci A., Demirci U., Coşkun U., Demir H., Algın E., Buğdaycı Başal F., Yamaç D., "The Tolerability of in the Adjuvant Treatment of Breast Cancer Comprising Sequential Anthracycline and Taxane Treatment: Single Center Experience", *Acta Oncologica Turcica*, vol. 47, pp. 8-15, 2014.